These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 9181268)

  • 21. Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): a new generation of calcium antagonists? Mibefradil International Study Group.
    Bernink PJ; Prager G; Schelling A; Kobrin I
    Hypertension; 1996 Mar; 27(3 Pt 1):426-32. PubMed ID: 8698449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of calcium channel blockers and beta blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. The Netherlands Working Group on Cardiovascular Research (WCN).
    van der Vring JA; Daniëls MC; Holwerda NJ; Withagen PJ; Schelling A; Cleophas TJ; Hendriks MG
    Angiology; 1999 Jun; 50(6):447-54. PubMed ID: 10378820
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The antihypertensive efficacy of the novel calcium antagonist mibefradil in comparison with nifedipine GITS in moderate to severe hypertensives with ambulatory hypertension.
    Lacourcière Y; Poirier L; Lefebvre J; Archambault F; Dalle Ave S; Ward C; Lindberg E
    Am J Hypertens; 1997 Feb; 10(2):189-96. PubMed ID: 9037327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Additional antianginal and anti-ischemic efficacy of mibefradil in patients concomitantly treated with long-acting nitrates for chronic stable angina pectoris.
    Frishman WH; Bittar N; Glasser S; Habib G; Smith W; Pordy R
    Clin Cardiol; 1998 Jul; 21(7):483-90. PubMed ID: 9669057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of calcium channel blockers and beta-adrenoceptor blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. Netherlands Working Group on Cardiovascular Research (WCN).
    Van Der Vring JA; Daniëls MC; Holwerda NJ; Withagen PJ; Schelling A; Cleophas TJ; Hendriks MG
    Br J Clin Pharmacol; 1999 May; 47(5):493-8. PubMed ID: 10336572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mibefradil: a new class of calcium-channel antagonists.
    Billups SJ; Carter BL
    Ann Pharmacother; 1998 Jun; 32(6):659-71. PubMed ID: 9640486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of calcium channel blockers and beta-blockers for patients with exercise-induced angina pectoris: beneficial effect of calcium channel blockers largely determined by their effect on heart rate.
    Cleophas TJ; van der Sluijs J; van der Vring JA; Daniëls MC; Holwerda KJ; Withagen AJ; Schelling A; Hendriks MG; Zwinderman AH
    J Clin Pharmacol; 1999 Jul; 39(7):738-46. PubMed ID: 10392329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mibefradil: a selective T-type calcium antagonist.
    Massie BM
    Am J Cardiol; 1997 Nov; 80(9A):23I-32I. PubMed ID: 9375939
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative pharmacological properties among calcium channel blockers: T-channel versus L-channel blockade.
    Noll G; Lüscher TF
    Cardiology; 1998; 89 Suppl 1():10-5. PubMed ID: 9570424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the efficacy and safety of once-daily versus twice-daily formulations of diltiazem in the treatment of systemic hypertension. The Canadian Multicenter Diltiazem-CD Hypertension Trial Group.
    Ruddy TD; Wright JM; Savard D; Handa SP; Chockalingam A; Boulet AP
    Cardiovasc Drugs Ther; 1995 Jun; 9(3):413-20. PubMed ID: 8527351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical experience with a once-daily, extended-release formulation of diltiazem in the treatment of hypertension.
    Graney WF
    Am J Med; 1992 Aug; 93(2A):56S-64S. PubMed ID: 1519637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mibefradil, a T-type channel-selective calcium antagonist: clinical trials in chronic stable angina pectoris.
    Massie BM
    Am J Hypertens; 1998 Apr; 11(4 Pt 3):95S-102S. PubMed ID: 9607373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: a multicenter placebo-controlled study. The Mibefradil International Study Group.
    Braun S; van der Wall EE; Emanuelsson H; Kobrin I
    J Am Coll Cardiol; 1996 Feb; 27(2):317-22. PubMed ID: 8557900
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimization of antihypertensive therapy with a novel, extended-release formulation of diltiazem: results of a practice-based clinical study.
    Neutel JM; Smith DH; Frishman WH
    Clin Ther; 1997; 19(6):1379-93. PubMed ID: 9444447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short-term hemodynamic effects of mibefradil in dogs with chronic heart failure: comparison with diltiazem.
    Shimoyama H; Sabbah HN; Tanimura M; Borzak S; Goldstein S
    J Pharmacol Exp Ther; 1998 May; 285(2):746-52. PubMed ID: 9580622
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of mibefradil, a new once-a-day, selective T-type calcium channel antagonist.
    Kobrin I; Charlon V; Lindberg E; Pordy R
    Am J Cardiol; 1997 Aug; 80(4B):40C-46C. PubMed ID: 9286853
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular effects of mibefradil in hypertensive patients with obstructive sleep apnea.
    Heitmann J; Grote L; Knaack L; Köhler U; Hinder M; Peter JH
    Eur J Clin Pharmacol; 1998; 54(9-10):691-6. PubMed ID: 9923569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Steady-state trough plasma mibefradil concentrations and correlation to blood pressure response in hypertensive patients with chronic renal disease.
    Pordy R; Woittiez A
    Int J Clin Pharmacol Res; 1998; 18(3):105-8. PubMed ID: 9825266
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized comparison of T-type versus L-type calcium-channel blockade on exercise duration in stable angina: results of the Posicor Reduction of Ischemia During Exercise (PRIDE) trial.
    Lee DS; Goodman S; Dean DM; Lenis J; Ma P; Gervais PB; Langer A;
    Am Heart J; 2002 Jul; 144(1):60-7. PubMed ID: 12094189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Mibefradil opens up a new class of calcium antagonists. Glasgow, 23 June 1996].
    Dtsch Med Wochenschr; 1996 Sep; 121(39 Suppl):1-4. PubMed ID: 9212757
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.